Resonate Group https://validator.w3.org/feed/docs/rss2.html EPA repeals power plant GHG rules, clearing path for new gas-fired generation US freezes Citgo board to protect pending $5.9-billion acquisition S&P Global: Refined product tightness deepens FDA launches pilot program to speed up sluggish phase 1 trials Connect’s Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope Insights: Prioritizing process safety management over profits across the refining industry (Pt. 1) Mayo Clinic teams with Thermo Fisher to form biomedical data group Precure Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech Newly formed Jaguar acquires Afib device assets from J&J GSK doubles down on Chimagen with $750M multiple myeloma wager Home Blog Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis After rejection, FDA approves Telix’s Pixclara, the first FET-PET imaging drug for brain cancer J&J’s Contineum-partnered depression drug flunks another phase 2 test In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy ExxonMobil awards contract to Wood for PNG LNG project As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety IEA: Ukrainian drone campaign degrades Russian refining resilience Lilly cans early experimental obesity drug after ‘high bar’ not met Axoltis misses the mark in phase 2 ALS study, but still strives to move towards the clinic Electra aims for $342M IPO to power inflammatory drug’s push through phase 3 Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon Singapore launches biotech-focused Boston hub to build on ‘centuries-old bond’ GE HealthCare mulls $1B imaging chemicals maker deal: Financial Times EIA: US crude inventories down 400,000 bbl Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi FERC approves Venture Global pipeline expansion to feed Plaquemines LNG plant S&P Global: Middle East crude flows to stay below prewar levels through 2027 Eni Ghana, Vitol Upstream Tano sign offshore Ghana MOUs Oil extends rally on further Middle East disruptions IEA sees oil demand decline deepening as Middle East disruptions persist Barclays conference: EOG prepares for steel inflation while Murphy weighs long-term portfolio options EIA forecasts continued growth in US crude oil production through 2026 Definium LSD drug goes 3 for 3 with another pivotal anxiety trial win Scientists boycott American Diabetes Association as fallout of June conference fracas escalates Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer The future of RAS inhibitors FDA delays approval decision for Exelixis’ tyrosine kinase inhibitor in colorectal cancer BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck Shell, partners sign agreement for Angola offshore blocks The signal that changes everything: understanding MRD in oncology drug development No more Nordisk as Novo goes it alone amid rebranding push Gulf Coast Midstream launches open season for Nash gas storage project EIA sees Brent near $90/bbl in second-half 2026 amid Middle East disruptions Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival Enbridge to acquire Tallgrass Energy’s crude transportation business for $2.55 billion Chutes & Ladders—Longtime Takeda R&D chief to depart next June J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg